A patient-centric approach to CAR-T therapy: from treatment selection to patient management

Watch exclusive interviews from the presenters of the Kite Satellite Symposium, ‘A patient-centric approach to CAR-T therapy: from treatment selection to patient management’ hosted during the European Hematology Association (EHA) 24th Congress in Amsterdam, Netherlands. Learn about the role of the multidisciplinary team throughout a patient’s CAR T-cell journey.

Addressing the needs of DLBCL and PMBCL with CAR T-cell therapy

Marie José Kersten, MD, PhD, from the University of Amsterdam, the Netherlands, describes the unmet needs in diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), and how the treatment paradigm in the relapsed/refractory setting has changed in recent years with introduction of CAR T-cell therapy.

The key role of patient selection and referral center communication

Prof. Kersten explains that not all patients are eligible for CAR T-cell therapy, hence an evaluation process and communication with referral centers is key. Prof. Kersten moves on to discuss the importance of patient follow-up.

The role of the nurse at each stage of the CAR-T treatment journey

Rose Ellard, BSc, MSc, from King’s College London, UK, discusses the central role of nurses within the multidisciplinary team involved in CAR T-cell therapy delivery, highlighting the value of a patient-centric approach.

Axicabtagene ciloleucel is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy. Axicabtagene ciloleucel must be administered at a qualified clinical setting.

Adverse events should be reported. For the UK, reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
For Ireland, reporting forms and information can be found at www.hpra.ie and can be reported to HPRA on +353 1 6764971.
Adverse events should also be reported to Gilead at safety_FC@gilead.com or +44 (0) 1223 897500.

YESCARTA® (axicabtagene ciloleucel), Kite and the Kite logo are registered trademarks of Kite Pharma Inc © 2019 Kite Pharma, Inc.